Douglas Ross Net Worth

The estimated Net Worth of Douglas T. Ross is at least $63 Thousand dollars as of 25 March 2022. Douglas Ross owns over 15,000 units of Oncocyte stock worth over $62,983 and over the last 4 years he sold OCX stock worth over $0. In addition, he makes $0 as Chief Medical Officer at Oncocyte.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Douglas Ross OCX stock SEC Form 4 insiders trading

Douglas has made over 1 trades of the Oncocyte stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 15,000 units of OCX stock worth $21,000 on 25 March 2022.

The largest trade he's ever made was buying 15,000 units of Oncocyte stock on 25 March 2022 worth over $21,000. On average, Douglas trades about 2,143 units every 0 days since 2020. As of 25 March 2022 he still owns at least 20,317 units of Oncocyte stock.

You can see the complete history of Douglas Ross stock trades at the bottom of the page.

Douglas Ross biography

Dr. Douglas Ross Ph.D., M.D. serves as Chief Medical Officer of the Company. Prior to joining Oncocyte, Dr. Ross was a principal of the Bethesda Group, LLC, biomedical consulting company that he co-founded in 2015. From 2014, until founding Bethesda Group, Dr. Ross served as Chief Scientific Officer of CardioDx, Inc. In 2011 Dr. Ross joined the Medical Science Division of Life Technologies and served as its Chief Scientific Officer on a consulting basis until that company was acquired by Thermo Fisher Scientific in 2013. Dr. Ross’s private sector career started in 2000 as Chief Scientific Officer of Applied Genomics, Inc. (AGI), a company he co-founded after post-doctoral training at Stanford University. AGI translated insights from gene expression patterns into immunohistochemistry multivariate assays targeted to actionable clinical problems. In 2009, Clarient, Inc., a national pathology reference laboratory, acquired AGI and Dr. Ross continued his role as Chief Scientific Officer. General Electric Healthcare acquired Clarient in December 2010, and Dr. Ross continued as Chief Scientific Officer, working with the business development and partnership teams at Clarient and capital teams at GE Healthcare. Dr. Ross obtained his M.D. and his Ph.D. in Pathology from the University of Washington while studying at the Fred Hutchinson Cancer Research Center in Seattle, Washington.

What's Douglas Ross's mailing address?

Douglas's mailing address filed with the SEC is C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE, CA, 92618.

Insiders trading at Oncocyte

Over the last 9 years, insiders at Oncocyte have traded over $16,389,842 worth of Oncocyte stock and bought 56,056,405 units worth $102,313,246 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Cell Therapeutics, Inc. Lin..., and Partners, L.P.Bradsher Neal.... On average, Oncocyte executives and independent directors trade stock every 37 days with the average trade being worth of $3,382,106. The most recent stock trade was executed by Josh Riggs on 11 April 2024, trading 3,390 units of OCX stock currently worth $10,001.

What does Oncocyte do?

oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.

Complete history of Douglas Ross stock trades at Oncocyte

Oncocyte executives and stock owners

Oncocyte executives and other stock owners filed with the SEC include:

• Ronald Andrews,
  President, Chief Executive Officer, Director
• Lyndal Hesterberg,
  Chief Scientific Officer
• Mitchell Levine,
  Chief Financial Officer
• Ronald A. Andrews Jr.,
  CEO, Pres & Director
• Cavan Redmond,
  Independent Chairman of the Board
• Andrew Last,
  Independent Director
• Andrew Arno,
  Independent Director
• Melinda Griffith,
  Independent Director
• Bob Yedid,
  Investor Relations
• Douglas Ross,
  Chief Medical Officer
• Padma Sundar,
  Senior Vice President - Marketing and Market Access
• Tony Kalajian,
  Senior Vice President, Chief Accounting Officer
• Albert Parker,
  Chief Operating Officer
• Dr. Michael D. West Ph.D.,
  Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc.
• Dr. Ekkehard Schutz M.D., Ph.D.,
  Chief Technology Officer
• Robert S. Seitz,
  Head of Immune Oncology
• Li Yu,
  VP, Controller & Principal Accounting Officer
• Gisela A. Paulsen,
  Chief Operating Officer
• Sara Riordan,
  Director of Medical Education
• Dr. Michael D. West,
  Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc.
• Dr. Douglas T. Ross M.D., Ph.D.,
  Chief Science Officer
• William Annett,
  Advisor
• Gisela Paulsen,
  Former President and COO
• Vida Investments, Llc Kamen...,
  
• Karen B. Chapman,
  Vice President of Research
• Alfred D Kingsley,
  Director
• Don M Bailey,
  Director
• William Annett,
  President and CEO
• Michael D West,
  Director
• Kristine C. Mechem,
  VP of Marketing
• Partners, L.P.Broadwood Cap...,
  
• Anish M. John,
  Chief Financial Officer
• Aditya P. Mohanty,
  Director
• Cell Therapeutics, Inc. Lin...,
  
• James Yang Liu,
  Sr Dir., Cntlr, PAO, Int PFO
• Jennifer L. Carter,
  Director
• Li Yu,
  VP Cntrllr/Prncpl Acctng Offcr
• Partners, L.P.Bradsher Neal...,
  
• Lou Silverman,
  Director
• Josh Riggs,
  CEO and President
• John Peter Gutfreund,
  
• Andrea S. James,
  Chief Financial Officer